<DOC>
	<DOCNO>NCT00000796</DOCNO>
	<brief_summary>To determine demographic , behavioral , clinical , geographic risk factor associate occurrence multidrug-resistant pulmonary tuberculosis ( MDRTB ) . To evaluate clinical microbiological response overall survival MDRTB patient treat levofloxacin-containing multiple-drug regimen choose hierarchical list . Per 9/28/94 amendment , ass whether persistent recurrent positive sputum culture patient show failure relapse due strain reinfection new strain . Among TB patient , increase progressive disease due emergence antimycobacterial drug-resistant strain Mycobacterium tuberculosis . Failure identify patient high risk MDRTB increase hazard treatment failure development resistance additional therapeutic agent . Efforts improve survival patient MDRTB depend improve method assess risk acquisition MDRTB identify drug susceptibility pattern timely fashion .</brief_summary>
	<brief_title>A Prospective Study Multidrug Resistance Pilot Study Safety Clinical Microbiologic Response Levofloxacin Combination With Other Antimycobacterial Drugs Treatment Multidrug-Resistant Pulmonary Tuberculosis ( MDRTB ) HIV-Infected Patients .</brief_title>
	<detailed_description>Among TB patient , increase progressive disease due emergence antimycobacterial drug-resistant strain Mycobacterium tuberculosis . Failure identify patient high risk MDRTB increase hazard treatment failure development resistance additional therapeutic agent . Efforts improve survival patient MDRTB depend improve method assess risk acquisition MDRTB identify drug susceptibility pattern timely fashion . Patients ask series question determine epidemiologic factor may predictive MDRTB . Patients determine low risk MDRTB refer another TB treatment protocol ( ACTG 222 ) , appropriate . Patients suspect primary acquire MDRTB confirm MDRTB offer regimen anti-TB therapy hierarchically ordered list drug , base patient 's resistance status ( suspect primary MDRTB , suspect acquire MDRTB , confirm MDRTB ) . The hierarchical list follow : isoniazid , rifampin , ethambutol , streptomycin , levofloxacin , ethionamide , cycloserine , capreomycin , aminosalicylic acid , clofazimine . Treatment administer daily least 6 month , intermittent schedule clinician 's discretion . Patients confirm MDRTB ( define know resistance least isoniazid rifampin within 6 month prior study entry ) receive minimum 18 month treatment follow sputum culture conversion . Follow-up perform every 4 week 8 week , every 8 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Capreomycin</mesh_term>
	<mesh_term>Ethionamide</mesh_term>
	<mesh_term>Streptomycin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<mesh_term>Clofazimine</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>Inclusion Criteria Patients must : Working diagnosis HIV infection . Working diagnosis pulmonary TB . Per 08/02/94 amendment , patient confirm MDRTB know susceptibility current episode baseline eligible epidemiologic study . FOR TREATMENT PILOT : Positive sputum AFB smear ( positive sputum culture TB within 6 month prior study entry ) . Assessment suspect primary , suspect acquire , AND/OR confirm MDRTB . Life expectancy least 2 week . Age &gt; = 18 year suspect MDRTB . Age &gt; = 13 year confirm MDRTB . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity resistance quinolones . Other disorder condition study drug contraindicate . Prior Medication : Excluded : More 6 week total therapy within 3 month prior study entry use three drug effective isolates . ( Per 08/02/94 amendment , patient protocol ACTG 222/CPCRA 019 MDRTB eligible rollover study regardless treatment duration ACTG 222/CPCRA 019 . )</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Isoniazid</keyword>
	<keyword>Tuberculosis , Pulmonary</keyword>
	<keyword>Pyrazinamide</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Ofloxacin</keyword>
	<keyword>Rifampin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Ethambutol</keyword>
	<keyword>Clofazimine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amikacin</keyword>
	<keyword>Drug Resistance , Microbial</keyword>
	<keyword>Cycloserine</keyword>
	<keyword>Capreomycin Sulfate</keyword>
	<keyword>Ethionamide</keyword>
	<keyword>Aminosalicylic Acids</keyword>
	<keyword>Streptomycin</keyword>
	<keyword>p-Aminosalicylic Acid</keyword>
</DOC>